Biotech entity
Each story carries 5.3 original sources on average, compared with 3.5 for the broader beat in this window. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Australian Government is most often covered alongside Ampol, which appears in 1 of these 3 stories.
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Each story carries 5.3 original sources on average, compared with 3.5 for the broader beat in this window. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Australian Government is most often covered alongside Ampol, which appears in 1 of these 3 stories. The 184-day window averages about 0.1 stories each week. Their average consequence score of 6.3 runs above the beat's 6.1 for that window. We currently track 3 Biotech stories that mention Australian Government, published between February 19, 2026 and August 21, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 757 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Australian Government. Shared-story counts are live from our verified record — not editorial picks.
Australia's push for low carbon liquid fuels creates a large new market for biologically derived feedstocks such as used cooking oil, tallow, and canola. The $5B feedstock stream currently exported could instead supply domestic bioprocessing and renewable fuel production. Ampol's Lytton refinery repurposing shows the industrial biotech supply chain taking shape.
Source: queenslandcountrylife.com.au · theland.com.au
A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Source: maitlandmercury.com.au · ulladullatimes.com.au
Experts are calling for a radical shift in antibiotic procurement, moving toward a subscription-based 'Netflix model' to incentivize the development of new drugs against resistant superbugs. This approach aims to decouple pharmaceutical revenue from sales volume, ensuring a steady supply of critical treatments as antimicrobial resistance escalates globally.
Australian Government is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
